Abbott Presents Results of TriClip Device and Navitor TAVI System for Tricuspid Regurgitation & Aortic Stenosis at EuroPCR 2022
Shots:
- The 30-day results from the TriClip (bRIGHT) study of TriClip & TriClip G4 TEER systems showed a high implant success rate (98%), TR reduction (71% vs 3% as baseline), 78% achieved NYHA Functional Class I/II, improvement by 57% from a baseline of 21% & 18-point improvement in KCCQ score
- The 1yr. results of the Navitor TAVI system showed the safety, effectiveness & durable response for sev. AS, 97.5% high procedural success rate, high rate of no/trace PVL (70.2%) & low rate of mild PVL & all-cause mortality (28.8% & 4.2%) indicating the active sealing cuff & effective in mitigating PVL
- The company highlighted the new results from the (EXPAND) study for MitraClip in HF patients with MR & Amplatzer Amulet for AF
Ref: Abbott | Image: Abbott
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
